Skip to content

EXOZ EXOZ Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

HTF
Heartflow, Inc. Common StockHTFL
$15.41M-25.5%
Photronics logo
PhotronicsPLAB
$3.9M+43.5%
Starfighters Space, Inc.
 logo
Starfighters Space, Inc. FJET
$244.99K
XTI Aerospace, Inc. logo
XTI Aerospace, Inc.XTIA
$756K-37.7%
Aptera Motors Corp.
 logo
Aptera Motors Corp. SEV
$10.84M-13.7%
Spectral AI, Inc. logo
Spectral AI, Inc.MDAI
$598K-31.3%

Other financials

Income statement

See full
Revenue$17.5K
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation

See full
Market cap$76.8M-5.6%
Enterprise value$76.57M+1.0%
P/S1,096.1×

Profitability

See full
Operating margin-14,489.6%
Net margin-2,909.1%
FCF margin-10,117.8%

Returns & leverage

See full
Return on equity-185.8%
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: EXOZ’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EXOZ's indefinite-lived research and development assets?
EXOZ (EXOZ) reported indefinite-lived research and development assets of $0 in Q4 2025.
What is the long-term trend for EXOZ's indefinite-lived research and development assets?
Over 2 years (2023 to 2025), EXOZ's indefinite-lived research and development assets has grown at a -100.0% compound annual growth rate (CAGR), from $1.1M to $0.
What does indefinite-lived research and development assets mean?
These are acquired research and development assets that have not yet reached commercial viability and are not subject to amortization. They represent the value of the company's pipeline and intellectual property portfolio that is currently in the development phase.